

In the Claims

Claims 1-44 (canceled).

Claim 45 (currently amended). An isolated or purified polynucleotide:

- a) encoding a polypeptide comprising SEQ ID NO: 1;
- b) encoding a HLA Human Leukocyte Antigen (HLA) binding fragment of SEQ ID NO: 1, said fragment comprising at least five consecutive amino acids of SEQ ID NO:1; or
- c) that is complementary to the along the full length of said polynucleotide of a) or b).

Claim 46 (currently amended). The isolated or purified polynucleotide according to claim 45, wherein said polynucleotide encodes [[a]]said polypeptide comprising SEQ ID NO: 1.

Claim 47 (currently amended). The isolated or purified polynucleotide according to claim 45, wherein said polynucleotide encodes [[a]]said HLA binding fragment of SEQ ID NO: 1.

Claim 48 (currently amended). The isolated or purified polynucleotide according to claim 45, wherein said polynucleotide is complementary to a polynucleotide that encodes a polypeptide comprising SEQ ID NO: 1 along the full length of said polynucleotide of a).

Claim 49 (currently amended). The isolated or purified polynucleotide according to claim 45, wherein said polynucleotide is complementary to a polynucleotide that encodes a HLA binding fragment of SEQ ID NO: 1 along the full length of said polynucleotide of b).

Claim 50 (currently amended). A vector comprising a promoter operably linked to a polynucleotide:

- a) encoding a polypeptide comprising SEQ ID NO: 1;

b) encoding a HLA-Human Leukocyte Antigen (HLA) binding fragment of SEQ ID NO: 1, said fragment comprising at least five consecutive amino acids of SEQ ID NO:1; or

c) that is complementary to the along the full length of said polynucleotide of a) or b).

Claim 51 (currently amended). The vector according to claim 50, wherein said polynucleotide encodes [[a]]said polypeptide comprising SEQ ID NO: 1.

Claim 52 (currently amended). The vector according to claim 50, wherein said polynucleotide encodes [[a]]said HLA binding fragment of SEQ ID NO: 1.

Claim 53 (currently amended). The vector according to claim 50, wherein said polynucleotide is complementary to a polynucleotide that encodes a polypeptide comprising SEQ ID NO: 1 along the full length of said polynucleotide of a).

Claim 54 (currently amended). The vector according to claim 50, wherein said polynucleotide is complementary to a polynucleotide that encodes a HLA binding fragment of SEQ ID NO: 1 along the full length of said polynucleotide of b).

Claim 55 (currently amended). [[A]]An isolated transformed host cell comprising a polynucleotide:

a) encoding a polypeptide comprising SEQ ID NO: 1;

b) encoding a HLA-Human Leukocyte Antigen (HLA) binding fragment of SEQ ID NO: 1, said fragment comprising at least five consecutive amino acids of SEQ ID NO:1; or

c) that is complementary to the along the full length of said polynucleotide of a) or b).

Claim 56 (currently amended). The isolated transformed host cell according to claim 55, wherein said polynucleotide encodes [[a]]said polypeptide comprising SEQ ID NO: 1.

Claim 57 (currently amended). The isolated transformed host cell according to claim 55, wherein said polynucleotide encodes [[a]]said HLA binding fragment of SEQ ID NO: 1.

Claim 58 (currently amended). The isolated transformed host cell according to claim 55, wherein said polynucleotide is complementary to a polynucleotide that encodes a polypeptide comprising SEQ ID NO: 1 along the full length of said polynucleotide of a).

Claim 59 (currently amended). The isolated transformed host cell according to claim 55, wherein said polynucleotide is complementary to a polynucleotide that encodes a HLA binding fragment of SEQ ID NO: 1 along the full length of the polynucleotide of b).

Claim 60 (currently amended). The isolated transformed host cell according to claim 55, wherein said polynucleotide is a vector comprising a promoter operably linked to a polynucleotide:

- a) encoding a polypeptide comprising SEQ ID NO: 1;
- b) encoding a HLA Human Leukocyte Antigen (HLA) binding fragment of SEQ ID NO: 1, said fragment comprising at least five consecutive amino acids of SEQ ID NO:1; or
- c) that is complementary to the along the full length of said polynucleotide of a or b.

Claim 61 (currently amended). The isolated transformed host cell according to claim 60, wherein said polynucleotide encodes [[a]]said polypeptide comprising SEQ ID NO: 1.

Claim 62 (currently amended). The isolated transformed host cell according to claim 60, wherein said polynucleotide encodes a said HLA binding fragment of SEQ ID NO: 1.

Claim 63 (currently amended). The isolated transformed host cell according to claim 60, wherein said polynucleotide is complementary to a polynucleotide that encodes a polypeptide

~~comprising SEQ ID NO: 1 along the full length of said polynucleotide of a).~~

Claim 64 (currently amended). The isolated transformed host cell according to claim 60, wherein said polynucleotide is complementary to a polynucleotide that encodes a HLA binding fragment of ~~SEQ ID NO: 1 along the full length of said polynucleotide of b).~~

Claim 65 (withdrawn-currently amended). A method of making a polypeptide comprising culturing ~~[[a]]~~an isolated transformed host cell according to claim 55 under conditions that allow for the production of said polypeptide.

Claim 66 (new). The isolated or purified polynucleotide according to claim 45, wherein said HLA binding fragment has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, and 35 amino acids.

Claim 67 (new). The vector according to claim 50, wherein said HLA binding fragment has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, and 35 amino acids.

Claim 68 (new). The isolated transformed host cell according to claim 55, wherein said HLA binding fragment has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, and 35 amino acids.

Claim 69 (new). The isolated transformed host cell according to claim 60, wherein said HLA binding fragment has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, and 35 amino acids.